Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 1/20 | 0.40 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.40 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.40 |
| ▸ | CYSLTR2 | Q9NS75 | 9/20 | 0.39 |
| ▸ | CYSLTR1 | Q9Y271 | 9/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.35 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | PPARA | Q07869 | 2/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.33 |
| ▸ | DAO | P14920 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18378474 | 0.89 | CYSLTR2 (0.47) | CYSLTR2CYSLTR1 | |
| SCHEMBL18242795 | 0.86 | ADRA2A (0.42) | ADRA2AADRA2BADRA2CCYSLTR2CYSLTR1 | |
| SCHEMBL18242473 | 0.85 | GABRA1 (0.44) | CYSLTR2CYSLTR1GABRA1GABRB2TSHR | |
| SCHEMBL7643940 | 0.82 | ADRA2A (0.44) | ADRA2AADRA2BADRA2CCYSLTR2CYSLTR1 | |
| SCHEMBL18377997 | 0.78 | ADRA2A (0.42) | ADRA2AADRA2BADRA2CCYSLTR2CYSLTR1 | |
| SCHEMBL18242027 | 0.78 | GABRA1 (0.41) | CYSLTR2CYSLTR1GABRA1GABRB2PPARA | |
| SCHEMBL19254463 | 0.78 | TSHR (0.55) | ADRA2AADRA2BADRA2CCYSLTR2CYSLTR1 | |
| SCHEMBL4843352 | 0.77 | ADRA2A (0.46) | ADRA2AADRA2BADRA2CCYSLTR2CYSLTR1 | |
| SCHEMBL9621039 | 0.77 | ADRA2A (0.46) | ADRA2AADRA2BADRA2CCYSLTR2CYSLTR1 | |
| SCHEMBL18892673 | 0.76 | LMNA (0.47) | ADRA2AADRA2BADRA2CCYSLTR2CYSLTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10451967-B2 | Acid- and radical-generating agent and method for generating acid and radical | FUJIFILM WAKO PURE CHEMICAL CORPORATION (JP) | 2019-10-22 | — | — | US | disclosed |
| US-20160342084-A1 | ACID- AND RADICAL-GENERATING AGENT AND METHOD FOR GENERATING ACID AND RADICAL | FUJIFILM WAKO PURE CHEMICAL CORPORATION (JP) | 2016-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10451967-B2 | Acid- and radical-generating agent and method for generating acid and radical | CBR1, HAO2, CBR3 | ADRA2A 476/4885ADRA2B 1291/4885ADRA2C 1281/4885 |
| US-20160342084-A1 | ACID- AND RADICAL-GENERATING AGENT AND METHOD FOR GENERATING ACID AND RADICAL | CBR1, HAO2, CBR3 | ADRA2A 476/4885ADRA2B 1291/4885ADRA2C 1281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.